BLA 125469 · Eli Lilly and CO
Trulicity
Dulaglutide · Injection · GLP-1 Receptor Agonist
NovelLast checked: Nov 20, 2026Latest source record: Mar 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2014
Sep 18, 2014
Approved uses
8
Original approval plus efficacy supplements
Registered trials
117
36 Phase 3, 10 recruiting
FAERS reports
89,369
23,531 serious, 1,706 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF THYROID C-CELL TUMORS In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined [see Warnings and Precautions ( 5.1 ), and Nonclinical Toxicology ( 13.1 )] . TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum...
What it is approved for
From the label in effect Jun 16, 2026.
TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. TRULICITY ® is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated ( 1 ): As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.
Mechanism: TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 17, 2022 Supplement 51 · Efficacy · priority review LetterLabel
- Sep 3, 2020 Supplement 36 · Efficacy LetterLabel
- Feb 21, 2020 Supplement 33 · Efficacy LabelLetter
- Jan 15, 2019 Supplement 23 · Efficacy LabelLetter
- Jun 29, 2018 Supplement 17 · Efficacy LetterLabel
- Jan 27, 2017 Supplement 8 · Efficacy LabelLetter
- Jan 27, 2017 Supplement 7 · Efficacy LabelLetter
- Sep 18, 2014 Original approval · Type 1 - New Molecular Entity NovelSummary ReviewLetterLabel
4 products under this application
- TRULICITY · DULAGLUTIDE 4.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
- TRULICITY · DULAGLUTIDE 1.5MG/0.5ML · INJECTABLE, INJECTION · Prescription
- TRULICITY · DULAGLUTIDE 3MG/0.5ML · INJECTABLE, INJECTION · Prescription
- TRULICITY · DULAGLUTIDE 0.75MG/0.5ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Dulaglutide" as an intervention, any sponsor and status, largest first.
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT04255433 · 13,299 participants · Start May 29, 2020 · Primary completion Jun 12, 2025
Drug: Tirzepatide; Dulaglutide · For: Type 2 Diabetes Mellitus
Sites: Birmingham, Alabama; Concord, California; Covina, California · 635 sites in all
- Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01394952 · 9,901 participants · Start Jul 22, 2011 · Primary completion Aug 21, 2018
Drug: Dulaglutide; Placebo · For: Cardiovascular Disease; Diabetes Mellitus, Type 2
Sites: Mobile, Alabama; Pell City, Alabama; Phoenix, Arizona · 300 sites in all
- PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesPivotal-lookingRecruiting
Brigham and Women's HospitalAcademic, hospital or other
NCT05390892 · 6,000 participants (planned) · Start Sep 26, 2022 · Primary completion Mar 1, 2029
Drug: SGLT2 inhibitor; GLP-1 receptor agonist · For: Type2Diabetes; ASCVD
Sites: Huntsville, Alabama; Scottsdale, Arizona; Los Angeles, California · 36 sites in all
- A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 DiabetesPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT03495102 · 1,842 participants · Start Apr 5, 2018 · Primary completion May 28, 2019
Drug: Dulaglutide · For: Diabetes Mellitus, Type 2
Sites: Chandler, Arizona; Mesa, Arizona; Phoenix, Arizona · 208 sites in all
- A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on MetforminPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00734474 · 1,202 participants · Start Aug 2008 · Primary completion Jun 2011
Drug: LY2189265; Sitagliptin and 3 more · For: Diabetes Mellitus, Type 2
Sites: Peoria, Arizona; Phoenix, Arizona; Tucson, Arizona · 99 sites in all
- Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.Pivotal-lookingCompleted
Novo Nordisk A/SNovo Nordisk (NVO)
NCT02648204 · 1,201 participants · Start Jan 6, 2016 · Primary completion Apr 10, 2017
Drug: semaglutide; Dulaglutide · For: Diabetes; Diabetes Mellitus, Type 2
Sites: Tuscumbia, Alabama; Chandler, Arizona; Phoenix, Arizona · 209 sites in all
- A Study in Participants With Type 2 Diabetes MellitusPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01064687 · 978 participants · Start Feb 2010 · Primary completion Nov 2011
Drug: LY2189265; Exenatide and 3 more · For: Diabetes Mellitus, Type 2
Sites: Goodyear, Arizona; Phoenix, Arizona; Cathedral City, California · 89 sites in all
Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic DisordersAcademic, hospital or other
NCT06449235 · 938 participants (planned) · Start Sep 2024 · Primary completion Apr 2025
Drug: Omarigliptin; Sulphonylureas and 7 more · For: Type2diabetes
Sites: Dhaka, Bangladesh
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- nausea10,580
- injection site pain10,019
- blood glucose increased9,960
- diarrhoea6,200
- vomiting5,949
- incorrect dose administered5,663
- inappropriate schedule of product administration3,843
- drug ineffective3,757
- weight decreased3,438
- decreased appetite3,281
- extra dose administered3,202
- injection site haemorrhage3,179
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 1 |
| 2012 | 4 |
| 2014 | 14 |
| 2015 | 1,678 |
| 2016 | 3,893 |
| 2017 | 6,225 |
| 2018 | 7,421 |
| 2019 | 9,334 |
| 2020 | 10,676 |
| 2021 | 12,619 |
| 2022 | 11,157 |
| 2023 | 9,512 |
| 2024 | 7,287 |
| 2025 | 5,875 |
| 2026 | 3,673 |
Recalls
2 FDA enforcement reports for this application.
Apr 5, 2022 · Class II · Completed
TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions
Aug 19, 2021 · Class II · Terminated
Labeling: Label error on declared strength - autoinjector devices labeled as 0.75 mg / 0.5 mL actually contain 1.5 mg / 0.5 mL of product.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Trulicity (Dulaglutide)
2024 spending
$5.45B
Beneficiaries
788,716
4,305,141 claims
Per beneficiary
$6,915
$467.75 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,284,873,062 |
| 2021 | $4,702,174,724 |
| 2022 | $6,225,291,668 |
| 2023 | $7,363,856,224 |
| 2024 | $5,454,134,725 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Safety issues of tirzepatide (pancreatitis and gallbladder or biliary disease) in type 2 diabetes and obesity: a systematic review and meta-analysis.
Zeng Q, Xu J, Mu X, et al. · Front Endocrinol (Lausanne) 2023 · Meta-Analysis, Systematic Review
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Gerstein HC, Colhoun HM, Dagenais GR, et al. · Lancet 2019 · Multicenter Study, Randomized Controlled Trial
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.
Nicholls SJ, Pavo I, Bhatt DL, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Equivalence Trial
- Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Kristensen SL, Rørth R, Jhund PS, et al. · Lancet Diabetes Endocrinol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Coskun T, Sloop KW, Loghin C, et al. · Mol Metab 2018 · Clinical Trial, Phase I, Randomized Controlled Trial
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Pratley RE, Aroda VR, Lingvay I, et al. · Lancet Diabetes Endocrinol 2018 · Clinical Trial, Phase III, Comparative Study
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.